- Home
- CMMB vs RDHL Comparison
CMMB vs RDHL Comparison
Compare CMMB & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | RDHL |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.5M | 3.3M |
| IPO Year | 2023 | 2012 |
Fundamental Metrics
Financial Performance| Metric | CMMB | RDHL |
|---|---|---|
| Price | $1.31 | $0.48 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 117.2K | ★ 209.2K |
| Earning Date | 11-19-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | $40.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.48 |
| 52 Week High | $3.55 | $2.26 |
Technical Indicators
Market Signals| Indicator | CMMB | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 25.39 | 34.08 |
| Support Level | N/A | N/A |
| Resistance Level | $1.83 | $1.07 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 13.07 | 12.97 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.